stoxline Quote Chart Rank Option Currency Glossary
Blueprint Medicines Corporation (BPMC)
113.46  -0.9 (-0.79%)    07-18 16:00
Open: 113.47
High: 115.45
Volume: 852,973
Pre. Close: 114.36
Low: 109.5
Market Cap: 7,105(M)
Technical analysis
2024-07-18 4:50:10 PM
Short term     
Mid term     
Targets 6-month :  142.37 1-year :  166.29
Resists First :  121.9 Second :  142.37
Pivot price 113.83
Supports First :  109.46 Second :  101.77
MAs MA(5) :  117.12 MA(20) :  111.67
MA(100) :  99.86 MA(250) :  78.83
MACD MACD :  3.2 Signal :  3.1
%K %D K(14,3) :  69.3 D(3) :  81.1
RSI RSI(14): 54.5
52-week High :  121.9 Low :  43.88
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ BPMC ] has closed above bottom band by 47.7%. Bollinger Bands are 17.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 115.5 - 116.28 116.28 - 116.92
Low: 108.05 - 108.79 108.79 - 109.4
Close: 112.35 - 113.58 113.58 - 114.6
Company Description

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 18 Jul 2024
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 - Morningstar

Tue, 16 Jul 2024
Blueprint Medicines: Overdue For A Breather (NASDAQ:BPMC) - Seeking Alpha

Sun, 14 Jul 2024
Blueprint Medicines (NASDAQ:BPMC) PT Raised to $115.00 at Morgan Stanley - American Banking and Market News

Tue, 02 Jul 2024
When Will Blueprint Medicines Corporation (NASDAQ:BPMC) Breakeven? - Simply Wall St

Thu, 06 Jun 2024
Insider Sale at Blueprint Medicines Corp (BPMC): Chief Medical Officer L. Hewes Sells Shares - Yahoo Finance

Thu, 30 May 2024
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib) - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 63 (M)
Shares Float 62 (M)
Held by Insiders 0.9 (%)
Held by Institutions 107 (%)
Shares Short 4,400 (K)
Shares Short P.Month 4,520 (K)
Stock Financials
EPS -4.83
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.96
Profit Margin -102.2 %
Operating Margin -82.1 %
Return on Assets (ttm) -24.4 %
Return on Equity (ttm) -79.6 %
Qtrly Rev. Growth 51.9 %
Gross Profit (p.s.) 0
Sales Per Share 4.5
EBITDA (p.s.) -6.84
Qtrly Earnings Growth 0 %
Operating Cash Flow -415 (M)
Levered Free Cash Flow -263 (M)
Stock Valuations
PE Ratio -23.5
PEG Ratio 0.5
Price to Book value 22.87
Price to Sales 25.17
Price to Cash Flow -17.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android